Tuesday, December 6, 2016

Economic burden of treatment for diffuse large b-cell lymphoma

A research team has confirmed expectations of higher healthcare utilization and costs with relapsed Diffuse Large B-Cell Lymphoma (DLBCL).



from Top Health News – ScienceDaily http://bit.ly/2gMqe9e
from Tumblr http://bit.ly/2hclyGQ
Posted by at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)